Ms. Fralick, if I may, I'll direct my final question to you.
The Government of Canada estimates that proposed reforms to Canada's drug pricing regulations—you referred to them as the PMPRB proposals—will save Canadians $13.2 billion over 10 years on patented drug costs. They say the new rules will save money for patients, employers and insurers, at the expense of drug industry profits.
In response, Innovative Medicines Canada has argued that these regulatory changes will result in fewer clinical trials and new medicines being available for sale. However, Doug Clark, executive director of the Patented Medicine Prices Review Board, has stated publicly that there is virtually zero correlation between prices and drugs coming to market, R and D spending and clinical trial intensity, in any country that the PMPRB has looked at.
How do you respond to Mr. Clark's position?